Table of Contents

Table of Contents

List of Tables

List of Figures

Section 1 - About the Company

Assertio Therapeutics Inc - Key Facts

Assertio Therapeutics Inc - Key Employees

Assertio Therapeutics Inc - Key Employee Biographies

Assertio Therapeutics Inc - Major Products and Services

Assertio Therapeutics Inc - History

Assertio Therapeutics Inc - Company Statement

Assertio Therapeutics Inc - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Section 2 – Company Analysis

Company Overview

Assertio Therapeutics Inc - Business Description

Product Category: CAMBIA

Overview

Performance

Product Category: Gralise

Overview

Performance

Product Category: Lazanda

Overview

Performance

Product Category: NUCYNTA Products

Overview

Performance

Product Category: Zipsor

Overview

Performance

R&D Overview

Assertio Therapeutics Inc - Corporate Strategy

Assertio Therapeutics Inc - SWOT Analysis

SWOT Analysis - Overview

Assertio Therapeutics Inc - Strengths

Assertio Therapeutics Inc - Weaknesses

Assertio Therapeutics Inc - Opportunities

Assertio Therapeutics Inc - Threats

Assertio Therapeutics Inc - Key Competitors

Section 3 – Company Financial Ratios

Financial Ratios - Capital Market Ratios

Financial Ratios - Annual Ratios

Performance Chart

Financial Performance

Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

Section 4 – Company’s Lifesciences Financial Deals and Alliances

Assertio Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Assertio Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

Assertio Therapeutics Inc, Recent Deals Summary

Section 5 – Company’s Recent Developments

Apr 01, 2019: Assertio Therapeutics names Jay Galeota to board of directors

Mar 28, 2019: Assertio Therapeutics Announces Favorable NUCYNTA Patent Ruling

Mar 06, 2019: Assertio Therapeutics announces fourth-quarter and full-year 2018 financial results

Feb 19, 2019: Assertio Therapeutics announces appointment of Heather L. Mason to Board of Directors

Nov 08, 2018: Assertio Therapeutics announces third-quarter 2018 financial results

Oct 29, 2018: Assertio Therapeutics appoints Daniel A. Peisert as Senior Vice President and Chief Financial Officer; Current CFO Phil B. Donenberg to Retire November 30, 2018

Oct 17, 2018: Assertio Therapeutics to participate in upcoming investor conferences

Aug 15, 2018: Depomed announces corporate name change to Assertio Therapeutics

Aug 08, 2018: Depomed announces second-quarter 2018 financial results

Jun 05, 2018: Depomed Appoints Phillip B. Donenberg As Chief Financial Officer

Section 6 – Appendix

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer

Assertio Therapeutics Inc (ASRT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Assertio Therapeutics Inc (Assertio), formerly Depomed Inc, is a specialty pharmaceutical company that develops and commercializes drugs for the treatment of pain and other diseases of central nervous system. Its product portfolio comprises drugs for the treatment of postherpetic neuralgia caused by viral infection, herpes zoster, or nerve damage; management of mild to moderate acute pain in adults; migraine attacks in adults of 18 years of age or above; and pain in cancer patients of 18 years of age and older. The company sells its products to wholesale distributors and retail pharmacies. Assertio also licenses Acuform, its proprietary gastroretentive drug delivery technology. Assertio is headquartered in Lake Forest, Illinois, the US.

Assertio Therapeutics Inc Key Recent Developments

Apr 01,2019 Assertio Therapeutics names Jay Galeota to board of directors
Mar 28,2019 Assertio Therapeutics Announces Favorable NUCYNTA Patent Ruling
Mar 06,2019 Assertio Therapeutics announces fourth-quarter and full-year 2018 financial results
Feb 19,2019 Assertio Therapeutics announces appointment of Heather L. Mason to Board of Directors

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company